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Pertussis remains a significant health problem, killing up to 200,000 infants annually. We are pursuing 
two complementary approaches to this problem, (1) engineering the adenylate cyclase toxin as an 
additional antigen for inclusion in the current accellular vaccine and (2) developing a neonatal antibody 
therapeutic to protect infants during the most vulnerable period before they are fully vaccinated.   
  
The current vaccine confers short-term immunity and prevents the symptoms of disease but does not 
reduce infection or transmission rates. The adenylate cyclase toxin (ACT) is the leading candidate for 
inclusion in future vaccines, yet there is surprisingly little data detailing the mechanisms by which ACT 
confers protection or its appropriateness for manufacturing and formulation as a part of a multicomponent 
vaccine. We have engineered this protein for improved production and stability and have identified a 
panel of neutralizing and non-neutralizing antibodies to aid in further engineering efforts. We are currently 
using the original ACT and our engineered variant in mouse immunization experiments to dissect ACT’s 
role in protection. Notably, addition of our engineered protein to the current acellular vaccine results in 
97% increased bacterial clearance during the early stages of disease, likely by protecting macrophages 
and neutrophils from toxin activites.  
  
To provide a therapeutic option before a new vaccine is lisenced, we have developed a humanized 
antibody, hu1B7, to both treat and prevent pertussis. This has been engineered for high affinity binding, 
reduced immunogenicity and extended serum half-life. We have shown hu1B7 is protective against 
disease in mouse and adolescent baboon models of disease. We have also characterized the antibodies’ 
mechanisms of action, using biochemical, structural and cellular assays. To determine if passive 
immunization could protect newborns from pertussis infection, hu1B7 was tested in newborn baboons. 
Two-day-old baboons received hu1B7 (40 mg/kg, IV) and five weeks later were infected with 108 cfu of B. 
pertussis. Animals were monitored for clinical signs of disease including leukocytosis, coughing, and 
bacterial colonization. Thu far, 7 hu1B7-treated and 6 control animals have completed the study.  
Antibody prophylaxis mitigated the clinical signs of pertussis, including leukocytosis (p = 0.004) and 
coughing, but as expected, did not prevent bacterial colonization (p = 0.15). As a step toward lowering the 
cost for developing world applications, we have generated and completed in vitro testing of an extended 
half-life version of hu1B7. Data from baboons treated with this variant will be reported.  
  
